{
  "docId": "019de076-7d6c-774e-85e8-ffe50da37251",
  "docSlug": "0b0d701714d17efa78c23c196990e90c",
  "documentTitle": "Genelux | Investor Presentation Deck | 37 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 37,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The slide compares mPFS results against SOC-AURELIA and ELAHARE benchmarks.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-7d6c-774e-85e8-ffe50da37251/9",
  "deckHref": "/decks/019de076-7d6c-774e-85e8-ffe50da37251",
  "deckJsonHref": "/decks/019de076-7d6c-774e-85e8-ffe50da37251.json",
  "deckAnchorHref": "/decks/019de076-7d6c-774e-85e8-ffe50da37251#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.28,
        "x": 0.04,
        "y": 0.185
      },
      "kind": "callout",
      "text": "Key Clinical Takeaways",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3ea42061-d08f-42ee-b09e-95cf253936d0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.26,
        "x": 0.06,
        "y": 0.32
      },
      "kind": "list",
      "text": "mPFS of 6.1 months (median 4 prior lines; 95%CI: 2.2-NA) for the six patients in Cohort 1 virus monotherapy – the dose used in Phase 2. SOC-AURELIA regimen (1-2 prior lines) - mPFS: 6.7 mos. ELAHARE (1-3 prior lines) - mPFS: 5.62 mos.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3456995a-c405-466c-a536-0e83af5965b3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.51,
        "y": 0.2
      },
      "kind": "list",
      "text": "Patient Background & Study Treatment: Heavily pre-treated PRROC patients with documented progressive disease. Cohort 1 received a Single cycle of intraperitoneal delivery on 2 consecutive days; total dose: 6x10^9 pfu, same dose as Phase II/III",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4104f471-aaaa-4eeb-b299-2ce73f9a84cb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.45,
        "x": 0.51,
        "y": 0.37
      },
      "kind": "list",
      "text": "Tolerability: No Dose Limiting Toxicity (DLT), No Maximum Tolerated Dose (MTD), No Grade 4 Adverse Events (AE)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4972fd12-07b5-4294-8f0d-7b572d47817a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.26,
        "x": 0.06,
        "y": 0.65
      },
      "kind": "list",
      "text": "Cohort 2/3 dosing done exponentially higher with no MTD reached.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "580abc39-5498-41c9-ae59-66cdbe3447cd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.45,
        "x": 0.51,
        "y": 0.54
      },
      "kind": "list",
      "text": "Antitumor activity: Clinical Benefit Rate: 73% (8/11), 4/11 patients had >2x PFS relative to immediate prior chemotherapy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c10f38c6-11a4-4eb9-a9da-94b22f09b263",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.51,
        "y": 0.71
      },
      "kind": "list",
      "text": "Translational Evidence: Activation of tumor-specific T cell response detected in blood, Documented immune activation in tumor microenvironment with significant influx of TILs, Favorable immune-related genetic signatures",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd9a098b-7456-47ad-8a70-a0608d94a7eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.94,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Phase 1b: Anti-tumor Activity as Monotherapy Leading into Combination",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a236f87-e120-4ff9-8288-a47c2b3a3e87",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 9,
      "beatId": "83a3aa16-5d5b-40f0-bd18-2beeecaa8bff",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The traction section highlights the results of phase 1b trials and the potential of Olvi-Vec.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}